Cargando…

Bayesian penalised likelihood reconstruction (Q.Clear) of (18)F-fluciclovine PET for imaging of recurrent prostate cancer: semi-quantitative and clinical evaluation

OBJECTIVE: (18)F-Fluciclovine (FACBC) is an amino acid PET radiotracer approved for recurrent prostate cancer imaging. We investigate the use of Bayesian penalised likelihood (BPL) reconstruction for (18)F-fluciclovine PET. METHODS: 15 (18)F-fluciclovine scans were reconstructed using ordered subset...

Descripción completa

Detalles Bibliográficos
Autores principales: Teoh, Eugene J, McGowan, Daniel R, Schuster, David M, Tsakok, Maria T, Gleeson, Fergus V, Bradley, Kevin M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The British Institute of Radiology. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6190769/
https://www.ncbi.nlm.nih.gov/pubmed/29303359
http://dx.doi.org/10.1259/bjr.20170727
_version_ 1783363623192625152
author Teoh, Eugene J
McGowan, Daniel R
Schuster, David M
Tsakok, Maria T
Gleeson, Fergus V
Bradley, Kevin M
author_facet Teoh, Eugene J
McGowan, Daniel R
Schuster, David M
Tsakok, Maria T
Gleeson, Fergus V
Bradley, Kevin M
author_sort Teoh, Eugene J
collection PubMed
description OBJECTIVE: (18)F-Fluciclovine (FACBC) is an amino acid PET radiotracer approved for recurrent prostate cancer imaging. We investigate the use of Bayesian penalised likelihood (BPL) reconstruction for (18)F-fluciclovine PET. METHODS: 15 (18)F-fluciclovine scans were reconstructed using ordered subset expectation maximisation (OSEM), OSEM + point spread function (PSF) modelling and BPL using β-values 100–600. Lesion maximum standardised uptake value (SUV(max)), organ SUV(mean) and standard deviation were measured. Deidentified reconstructions (OSEM, PSF, BPL using β200–600) from 10 cases were visually analysed by two readers who indicated their most and least preferred reconstructions, and scored overall image quality, noise level, background marrow image quality and lesion conspicuity. RESULTS: Comparing BPL to OSEM, there were significant increments in lesion SUV(max) and signal-to-background up to β400, with highest gain in β100 reconstructions (mean ΔSUV(max) 3.9, p < 0.0001). Organ noise levels increased on PSF, β100 and β200 reconstructions. Across BPL reconstructions, there was incremental reduction in organ noise with increasing β, statistically significant beyond β300–500 (organ-dependent). Comparing with OSEM and PSF, lesion signal-to-noise was significantly increased in BPL reconstructions where β ≥ 300 and  ≥ 200 respectively. On visual analysis, β 300 had the first and second highest scores for image quality, β500 and β600 equal highest scores for marrow image quality and least noise, PSF and β 200 had first and second highest scores for lesion conspicuity. For overall preference, one reader preferred β 300 in 9/10 cases and the other preferred β 200 in all cases. CONCLUSION: BPL reconstruction of (18)F-fluciclovine PET images improves signal-to-noise ratio, affirmed by overall reader preferences. On balance, β300 is suggested for (18)F-fluciclovine whole body PET image reconstruction using BPL. ADVANCES IN KNOWLEDGE: The optimum β is different to that previously published for (18)F-fluorodeoxyglucose, and has practical implications for a relatively new tracer in an environment with modern reconstruction technologies.
format Online
Article
Text
id pubmed-6190769
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher The British Institute of Radiology.
record_format MEDLINE/PubMed
spelling pubmed-61907692019-05-01 Bayesian penalised likelihood reconstruction (Q.Clear) of (18)F-fluciclovine PET for imaging of recurrent prostate cancer: semi-quantitative and clinical evaluation Teoh, Eugene J McGowan, Daniel R Schuster, David M Tsakok, Maria T Gleeson, Fergus V Bradley, Kevin M Br J Radiol Short Communication OBJECTIVE: (18)F-Fluciclovine (FACBC) is an amino acid PET radiotracer approved for recurrent prostate cancer imaging. We investigate the use of Bayesian penalised likelihood (BPL) reconstruction for (18)F-fluciclovine PET. METHODS: 15 (18)F-fluciclovine scans were reconstructed using ordered subset expectation maximisation (OSEM), OSEM + point spread function (PSF) modelling and BPL using β-values 100–600. Lesion maximum standardised uptake value (SUV(max)), organ SUV(mean) and standard deviation were measured. Deidentified reconstructions (OSEM, PSF, BPL using β200–600) from 10 cases were visually analysed by two readers who indicated their most and least preferred reconstructions, and scored overall image quality, noise level, background marrow image quality and lesion conspicuity. RESULTS: Comparing BPL to OSEM, there were significant increments in lesion SUV(max) and signal-to-background up to β400, with highest gain in β100 reconstructions (mean ΔSUV(max) 3.9, p < 0.0001). Organ noise levels increased on PSF, β100 and β200 reconstructions. Across BPL reconstructions, there was incremental reduction in organ noise with increasing β, statistically significant beyond β300–500 (organ-dependent). Comparing with OSEM and PSF, lesion signal-to-noise was significantly increased in BPL reconstructions where β ≥ 300 and  ≥ 200 respectively. On visual analysis, β 300 had the first and second highest scores for image quality, β500 and β600 equal highest scores for marrow image quality and least noise, PSF and β 200 had first and second highest scores for lesion conspicuity. For overall preference, one reader preferred β 300 in 9/10 cases and the other preferred β 200 in all cases. CONCLUSION: BPL reconstruction of (18)F-fluciclovine PET images improves signal-to-noise ratio, affirmed by overall reader preferences. On balance, β300 is suggested for (18)F-fluciclovine whole body PET image reconstruction using BPL. ADVANCES IN KNOWLEDGE: The optimum β is different to that previously published for (18)F-fluorodeoxyglucose, and has practical implications for a relatively new tracer in an environment with modern reconstruction technologies. The British Institute of Radiology. 2018-05 2018-01-19 /pmc/articles/PMC6190769/ /pubmed/29303359 http://dx.doi.org/10.1259/bjr.20170727 Text en © 2018 The Authors. Published by the British Institute of Radiology http://creativecommons.org/licenses/by/4.0/ This is an open access article under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.
spellingShingle Short Communication
Teoh, Eugene J
McGowan, Daniel R
Schuster, David M
Tsakok, Maria T
Gleeson, Fergus V
Bradley, Kevin M
Bayesian penalised likelihood reconstruction (Q.Clear) of (18)F-fluciclovine PET for imaging of recurrent prostate cancer: semi-quantitative and clinical evaluation
title Bayesian penalised likelihood reconstruction (Q.Clear) of (18)F-fluciclovine PET for imaging of recurrent prostate cancer: semi-quantitative and clinical evaluation
title_full Bayesian penalised likelihood reconstruction (Q.Clear) of (18)F-fluciclovine PET for imaging of recurrent prostate cancer: semi-quantitative and clinical evaluation
title_fullStr Bayesian penalised likelihood reconstruction (Q.Clear) of (18)F-fluciclovine PET for imaging of recurrent prostate cancer: semi-quantitative and clinical evaluation
title_full_unstemmed Bayesian penalised likelihood reconstruction (Q.Clear) of (18)F-fluciclovine PET for imaging of recurrent prostate cancer: semi-quantitative and clinical evaluation
title_short Bayesian penalised likelihood reconstruction (Q.Clear) of (18)F-fluciclovine PET for imaging of recurrent prostate cancer: semi-quantitative and clinical evaluation
title_sort bayesian penalised likelihood reconstruction (q.clear) of (18)f-fluciclovine pet for imaging of recurrent prostate cancer: semi-quantitative and clinical evaluation
topic Short Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6190769/
https://www.ncbi.nlm.nih.gov/pubmed/29303359
http://dx.doi.org/10.1259/bjr.20170727
work_keys_str_mv AT teoheugenej bayesianpenalisedlikelihoodreconstructionqclearof18ffluciclovinepetforimagingofrecurrentprostatecancersemiquantitativeandclinicalevaluation
AT mcgowandanielr bayesianpenalisedlikelihoodreconstructionqclearof18ffluciclovinepetforimagingofrecurrentprostatecancersemiquantitativeandclinicalevaluation
AT schusterdavidm bayesianpenalisedlikelihoodreconstructionqclearof18ffluciclovinepetforimagingofrecurrentprostatecancersemiquantitativeandclinicalevaluation
AT tsakokmariat bayesianpenalisedlikelihoodreconstructionqclearof18ffluciclovinepetforimagingofrecurrentprostatecancersemiquantitativeandclinicalevaluation
AT gleesonfergusv bayesianpenalisedlikelihoodreconstructionqclearof18ffluciclovinepetforimagingofrecurrentprostatecancersemiquantitativeandclinicalevaluation
AT bradleykevinm bayesianpenalisedlikelihoodreconstructionqclearof18ffluciclovinepetforimagingofrecurrentprostatecancersemiquantitativeandclinicalevaluation